Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease - Summary - MDSpire

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease

  • By

  • Lindsay A. Welikovitch

  • Derek H. Oakley

  • Rachel E. Bennett

  • Alberto Serrano-Pozo

  • Haoyang Zhu

  • Nancy E. Ruiz-Uribe

  • Theodore J. Zwang

  • Lori B. Chibnik

  • Teresa Gomez-Isla

  • Matthew P. Frosch

  • Donald S. Marks

  • Stephen Salloway

  • Charles Bernick

  • David Greeley

  • Caitlin S. Latimer

  • Amber Nolan

  • R. Matthew Hutchison

  • Carrie E. Rubel

  • Thierry Bussiere

  • Edward D. Plowey

  • C. Dirk Keene

  • Bradley T. Hyman

  • June 16, 2026

  • 0 min

Share

Objective:

To conduct a comprehensive neuropathological analysis of aducanumab-treated Alzheimer’s disease patients and compare findings with untreated patients.

Approach:
    Key Findings:
    • Aducanumab treatment resulted in specific neuropathological changes in the brains of treated patients.
    • Only eight autopsy cases of aducanumab-treated individuals have been reported previously, highlighting the limited data available.
    • The study provides insights into the mechanisms and long-term consequences of aducanumab treatment.
    Interpretation:

    The findings contribute to understanding the effects of anti-Aβ immunotherapy on the human brain in Alzheimer's disease.

    Limitations:
    • The sample size of treated patients is small, limiting the generalizability of findings.
    • Limited neuropathological data from treated individuals prior to this study.
    Conclusion:

    This study enhances the understanding of aducanumab's impact on neuropathology in Alzheimer's disease.

Original Source(s)

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease

  • by Lindsay A. Welikovitch, Derek H. Oakley, Rachel E. Bennett, Alberto Serrano-Pozo, Haoyang Zhu, Nancy E. Ruiz-Uribe, Theodore J. Zwang, Lori B. Chibnik, Teresa Gomez-Isla, Matthew P. Frosch, Donald S. Marks, Stephen Salloway, Charles Bernick, David Greeley, Caitlin S. Latimer, Amber Nolan, R. Matthew Hutchison, Carrie E. Rubel, Thierry Bussiere, Edward D. Plowey, C. Dirk Keene, Bradley T. Hyman

  • June 16, 2026

Related Content

Editorial: Cross-talk of synaptic proteins in neurological diseases

Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis